US Patent

US11446380 — Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

Composition of Matter · Assigned to Alnylam Pharmaceuticals Inc · Expires 2035-10-09 · 9y remaining

Vulnerability score 12/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects RNAi agents that target the HAO1 gene and methods for using them to inhibit HAO1 expression and treat PH1.

USPTO Abstract

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the HAO1 gene, and methods of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.

Drugs covered by this patent

Patent Metadata

Patent number
US11446380
Jurisdiction
US
Classification
Composition of Matter
Expires
2035-10-09
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.